$120.85$150.99
Prepare to embark on a sensory journey with the Bosco Apple, a fruit that transcends the ordinary and promises an unparalleled taste experience. These apples are nothing short of nature’s masterpiece, celebrated for their distinctive blend of flavors and their captivating visual allure.
Availability: In Stock
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
₹150
INTRODUCTION REDAPT CT TABLET contains Ferric citrate which belongs to the group of medicines called Phosphate binder and Iron replacement agents. It is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis and for the treatment of iron...
REDAPT CT TABLET contains Ferric citrate which belongs to the group of medicines called Phosphate binder and Iron replacement agents. It is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis and for the treatment of iron deficiency anaemia in adults with chronic kidney disease not on dialysis.
REDAPT CT TABLET is not recommended for use in patients with iron overload syndromes (hemochromatosis). Contact your doctor before taking. REDAPT CT TABLET should be used with caution in patients with kidney disease.
REDAPT CT TABLET should be used with caution in pregnant and breast-feeding women. Contact your doctor before taking. Safety data of REDAPT CT TABLET in children and adolescents has not been established yet. It should be used with caution in elderly patients aged 65 years or above.
The most common side effects of taking REDAPT CT TABLET are nausea, vomiting, diarrhoea, constipation, or abdominal pain. Contact your physician if any of the symptoms worsen.
It is used in adults to treat:
Hyperphosphatemia in chronic kidney disease on dialysis:
REDAPT CT TABLET binds to dietary phosphate in the gastrointestinal tract, precipitates as ferric phosphate and is excreted in stools as it is insoluble. Thus, lowers the serum phosphate concentration.
Iron deficiency anaemia in chronic kidney disease not on dialysis:
REDAPT CT TABLET enters the blood, binds to the transferrin protein and is incorporated into haemoglobin. Thus, increases haemoglobin levels and iron levels in the body.
Take REDAPT CT TABLET as advised by your physician. Swallow the medicines with a glass of water. Do not crush or chew the medicine. Your physician will decide the correct dose and duration for you depending upon your age, body weight and disease condition.
Nausea, vomiting:
Stick to simple meals. Avoid eating oily or spicy foods. Contact your doctor if nausea and vomiting did not improve.
Diarrhoea:
Drink lots of fluids, such as water or fruit juices to keep you hydrated. Do not take any medicine on your own for treating diarrhoea. Contact your doctor if diarrhoea did not improve.
Constipation:
Eat fibre rich foods such as fresh fruits, vegetables, and cereals. Drink more water and exercise regularly. Contact your doctor if constipation did not improve.
Stomach pain:
Try to rest and relax. Eat small meals but take frequently. Keep a heat pad on your stomach. Contact your doctor if stomach pain worsens.
Safety and effectiveness of REDAPT CT TABLET in pregnant women or women planning to have a baby has not been established yet. Contact your doctor before taking.
Safety and effectiveness of REDAPT CT TABLET in breastfeeding women has not been established yet. Contact your doctor before taking.
Do not take REDAPT CT TABLET if you are allergic to Ferric Citrate or any other ingredients of this medicine.
REDAPT CT TABLET is not recommended for use if you have:
Use in paediatrics:
Safety and effectiveness of REDAPT CT TABLET in children and adolescents has not been established yet. Contact your doctor before taking.
Use in geriatrics:
REDAPT CT TABLET should be used with caution in elderly patients aged 65 years or above. Contact your doctor before taking.
A. Drug-Drug interactions:
Before taking REDAPT CT TABLET, inform your doctor if you are taking any of the following medicine:
Overdosage:
If you or anyone else accidentally take too much of REDAPT CT TABLET, consult your doctor immediately or visit the nearby hospital. Symptoms of overdosage are excessive elevations in iron stores in the body.
| Drug | : | Ferric citrate |
| Pharmacological Category | : | Phosphate binder and Iron replacement medicines, Hyperphosphatemia in Chronic Kidney Disease on Dialysis, Iron Deficiency Anaemia in Chronic Kidney Disease Not on Dialysis |
| Therapeutic Indication | : | Pain relief |
| Dosage Forms | : | Tablet, Capsule |
How REDAPT CT TABLET works?
Hyperphosphatemia in Chronic Kidney Disease on Dialysis:
REDAPT CT TABLET binds to dietary phosphate in the gastrointestinal tract and precipitates as ferric phosphate and is excreted in stools. Thus, lowers the serum phosphate concentration.
Iron Deficiency Anaemia in Chronic Kidney Disease Not on Dialysis:
REDAPT CT TABLET enters the blood and binds to the transferrin protein and can be incorporated into haemoglobin. Thus, increases haemoglobin levels and iron levels in the body.
What are the side effects of taking REDAPT CT TABLET?
The most common side effects of taking REDAPT CT TABLET are nausea, vomiting, diarrhoea, constipation, abdominal pain, high potassium levels in blood and change in stool colour. Contact your physician if any of the symptoms worsen.
Who should not take REDAPT CT TABLET?
REDAPT CT TABLET is not recommended for use in patients with iron overload syndromes (hemochromatosis). Contact your doctor for more information before taking this medicine.
What REDAPT CT TABLET and what it is used for?
REDAPT CT TABLET contains Ferric citrate which belongs to the group of medicines called Phosphate binder and Iron replacement medicines. It is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis and for the treatment of iron deficiency anaemia in adults with chronic kidney disease not on dialysis.
Can REDAPT CT TABLET be used in pregnancy?
Safety and effectiveness of REDAPT CT TABLET in pregnant women or women planning to have a baby has not been established yet. Contact your doctor before taking.
1. KD Tripathi. Haematinics and Erythropoietin. Essentials of medical pharmacology. Eighth edition. 2019. Page- 645.
2. Volker H Haase. The ins and outs of ferric citrate. NIH. National library of medicine, National centre for biotechnology information. Pubmed.gov. April 2022. [Accessed on 6th July 2022] https://pubmed.ncbi.nlm.nih.gov/35314048/
3. Ajay Gupta. Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity. NIH. National library of medicine, National centre for biotechnology information. PubMed Central. October 2014. [Accessed on 6th July 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210856/
4. Keryx Biopharmaceuticals, Inc. U.S. Food & Drug Administration (FDA). [Revised in November 2017] [Accessed on 6th July 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205874s013lbl.pdf
5. Keryx Biopharmaceuticals inc. Ferric Citrate. [Revised in March 2021] [Accessed on 6th July 2022] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aadd18e0-3752-11e4-8510-0800200c9a66
6. Akebia Therapeutics. Ferric Citrate. [Revised in July 2021] [Accessed on 6th July 2022] https://www.auryxiahcp.com/static/Digital_IDA_Branded_Tearsheet_Final%20Upload-292146239d3b38755f7dec7fd4fa59be.pdf
7. Keryx Biopharmaceuticals, Inc. Ferric Citrate. [Revised in March 2021] [Accessed on 6th July 2022] https://www.auryxia.com/wp-content/uploads/Auryxia_PI.pdf
Written By Dr. Shruthi M R, BDS
Last updated on 11 Jan 2023 | 10:32 AM(IST)